search for




 

Risk Factor Associated with Recurrence after OM-89 (Uro-Vaxom®) Treatment for Female Recurrent Cystitis
Urogenit Tract Infect 2019 Aug;14(2):42-5
Published online August 30, 2019;  https://doi.org/10.14777/uti.2019.14.2.42
Copyright © 2019 Korean Association of Urogenital Tract Infection and Inflammation.

Ji-Yeon Han

Department of Urology, Pusan National University Yangsan Hospital, Pusan National University School of Medicine, Busan, Korea
Correspondence to: Ji-Yeon Han
https://orcid.org/0000-0002-1695-3100
Department of Urology, Pusan National University Yangsan Hospital, Pusan National University School of Medicine, 20 Geumo-ro, Mulgeum-eup, Yangsan 50612, Korea
Tel: +82-55-360-2676, Fax: +82-55-360-2164
E-mail: jyincomo@gmail.com
Received April 18, 2019; Revised May 10, 2019; Accepted May 10, 2019.
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
Abstract
Purpose: This study evaluated the risk factors associated with recurrence OM-89 (Uro-Vaxom®) treatment for female recurrent cystitis.
Materials and Methods: The medical records of patients who received OM-89 for at least six months were reviewed retrospectively. Patients were excluded from the analysis if they had an abnormal lower urinary tract anatomy, residual urine volume ≥200 ml, a history of genitourinary tuberculosis, urological cancer or pelvic radiation, indwelling urinary catheter, or had genitourinary surgery within the previous six months. Patients were categorized into two groups: (1) no recurrence and (2) recurrent cystitis after OM-89. The risk factors in the two groups were compared. The recurrent cystitis was defined as two more infections in six months or three or more in one year.
Results: A total of 52 female were included. Group 1 had 35 (67.3%) patients and group 2 had 17 (32.7%) patients. Before and after the OM-89, the mean cystitis episodes for six months of groups 1 and 2 were 4.19±4.60 (range, 2-24) and 1.17±1.79 (range, 0-6), respectively, which were decreased significantly (p <0.001). For recurrence after the OM-89, the only risk factor was uncontrolled diabetes (fasting plasma glucose level >120 mg/dl±casual plasma glucose >180 mg/dl) (p=0.002). No significant differences in the age, menopause, daily water intake, hormone replacement therapy or history of extended-spectrum beta-lactamase-producing Escherichia coli were observed between the two groups.
Conclusions: OM-89 was effective in the management of recurrent cystitis in female. On the other hand, uncontrolled diabetes was a risk factor for treatment failure of OM-89.
Keywords : Cystitis; Diabetes mellitus; Immunotherapy; Recurrence


August 2019, 14 (2)

  • The official journal of

    The Korean Association of Urogenital Tract Infection and Inflammation

    The Korean Continence Society

    The Han-nam Urological Association

    The Korean Society of Geriatric Urological Care